MADISON, NJ / ACCESSWIRE / June 3, 2024 / G&L Healthcare Advisors is delighted to announce that Richard Edmunds, a 25-year veteran in regulatory affairs, will take on a new client engagement role and lead our U.S. West Coast business expansion, based out of G&L’s San Diego, California, office.
Bringing decades of regulatory and clinical development experience, Richard will partner with both biotech and pharma customers to expedite drug development and product launch. Richard has a strong track record of helping over 50 companies secure regulatory approval.
Richard brings a unique and compelling combination of technical expertise and business acumen that helps our clients achieve their goals, whatever their stage of development.
He has assisted clients in initiating proof-of-concept studies and securing funding; reaching Ph1/2 clinical trial inflection point; gearing up for product approval and launch; increasing revenue through global expansion; or implementing cost-effective models for post-approval activities, technology solutions, and more.
Commenting on Richard’s appointment, G&L’s COO, Dave Yungvirt, said:
“We are excited that Richard has agreed to help take G&L to the next level, as part of our continued growth, serving our West Coast clients to ultimately meet patient needs.”
Schedule your appointment with Richard today: https://calendly.com/redmunds-e3vm/g-l-health-introduction
About G&L Healthcare Advisors
Built upon the foundation of decades of delivering industry-leading regulatory and quality services, G&L Healthcare Advisors (G&L) is rapidly evolving into a trusted and innovative biopharmaceutical solutions provider.
Harnessing both global expertise and cutting-edge technology, G&L is expertly positioned to support the pharmaceutical, biopharmaceutical and biotechnology industry as it undergoes a scientific renaissance.
We aim to provide a single, unified source of best-in-class solutions across the entire product lifecycle, spanning business model organization, drug development, regulatory and quality, commercial launch, and market access.
Contact Information
Jonathan Walmsley
Communications Manager
jwalmsley@gandlhealth.com
SOURCE: G&L Healthcare Advisors
View the original press release on newswire.com.
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…
Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…
